Earnings Call · Q2 FY2024·2024-08-22

Q2 24EPS -14.29%·Rev n/aQ1 24EPS +3.70%·Rev n/aQ4 23EPS +86.11%·Rev n/aQ3 23EPS +6.98%·Rev n/a⚠ consensus missing

ENDRA Life Sciences Inc. NDRA

Yvonne Briggs — Investor Relations

Alexander Tokman — Chief Executive Officer

Ziad Rouag — Unknown (likely executive or senior management)

Michael Thornton — Unknown (likely executive or senior management)

Richard Jacroux — Chief Financial Officer

+62.4%1d on move date+62.7% vs SPY3d+3.4%5d−3.4%

Research tier

Behavioral profile computed for 5 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more NDRA calls or request research access.

More NDRA calls Browse calls Request research access